Transforming Patient Lives.
Adraxe is led by a distinguished team of industry veterans and clinical pioneers dedicated to solving the complex engineering and clinical challenges of drug-resistant epilepsy.
Our Mission
To pioneer precision, targeted therapies that empower patients with drug-resistant epilepsy to regain control and start living more.
Why am I working here?
"We are building the first truly individualized, closed-loop system that respects the brain's natural architecture while delivering unmatched efficacy. It's an exciting and important mission in neuromodulation today."
Company Values
Go where the science takes us
We rely on rigorous clinical evidence and true precision therapy to guide our breakthrough innovations.
Additional values coming soon...
The Team
Industry Leaders in Neuro-technology
Lothar Krinke, PhD
CEO of Adraxe
Former CEO of Newronika and Welcony. Previously led Medtronic's Brain Modulation business bringing extensive commercialization expertise.
"We go where the science takes us"
Lindsey Jardine
VP of Clinical, Regulatory, and Quality Affairs
10+ years in medical devices, bringing critical expertise in navigating FDA, CE Mark, and PMDA regulatory pathways for breakthrough devices.
"Hope is born in the moments when determination meets possibility."
Carl Wahlstrand
VP of Engineering
25 years in Neuromodulation. Former Senior Director at Synchron and Medtronic Technical Fellow holding 110+ patents.
"At Adraxe, we embrace the pressure that comes with implantable neuromodulation—designing systems clinicians can trust and patients can rely on every moment of every day."
Our Trusted Advisors
A distinguished team of thought leaders guiding our vision and growth.
Dr. Elizabeth Tyler-Kabara
Pediatric Neurosurgeon
Dr. Jacqueline French
Epileptologist
Dr. John Rolston
Neurosurgeon
Tim Marjenin
Regulatory Expert
Dr. Luke Bashford
Scientific Advisor
Dr. Shruti Agashe
Epileptologist
Dr. Steven Tobochnik
Epileptologist